Schering Corporation

Merck Sharp + Dohme Corp.

Jean E Lachowicz

Wei W Wang

Samuel Chackalamannil

Craig D Boyle

Joseph A Hedrick

Unmesh G Shah

Eric L Gustafson

Duane A Burnett

Wen-Lian Wu

Martin Domalski

Mary Ann Caplen

Richard Spring

The compound having the structural formula I or a pharmaceutically acceptable salt thereof, is disclosed, as well as its use in the treatment of central nervous system diseases, in particular Parkinson's disease, Extra Pyramidal Syndrome, restless legs syndrome and attention deficit hyperactivity disorder, pharmaceutical compositions comprising it, and combinations with other agents.

7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-E]-[1,2,4]-triazolo-[1,5-C]-pyrimidin-5-amine

7-[2-[4-(6-fluoro-3-methyl-1,2-benzisoxazol-5-yl)-1-piperazinyl]ethyl]-2-(1-propynyl)-7H-pyrazolo-[4,3-e]-[1,2,4]-triazolo-[1,5-C]-pyrimidin-5-amine

The present invention provides an isolated mammalian adenosine receptor, isolated or recombinant nucleic acids and recombinant vectors encoding the same, host cells comprising the nucleic acids and vectors, and methods of making the receptor using the host cells. This invention further provides antibodies and antigen binding fragments thereof which specifically bind to the receptor and are useful for treating medical conditions caused or mediated by adenosine. Also provided are screening methods for identifying specific agonists and antagonists of the mammalian adenosine receptor.

Adenosine receptor

The present invention provides compounds, which, are novel antagonists for Dreceptors as well as methods for preparing such compounds. In another embodiment, the invention provides pharmaceutical compositions comprising such Dreceptor antagonists as well as methods of using them to treat CNS disorders, obesity, metabolic disorders, eating disorders such as hyperphagia, and diabetes.

[object Object]

Growing community of inventors

Berkeley Heights, NJ, United States of America

Jean E Lachowicz